Marinus Pharma Stock (NASDAQ:MRNS), Trade Ideas

Marinus Pharma

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

News

Penny Stocks

Price Target

Markets

Analyst Ratings

Trading Ideas

AMGN

JBHT

MRNS

STRA

URBN

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

laboratory-563423_1280

Analyst Color

Equities

Downgrades

Marinus Pharmaceuticals&#39; phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus fails interim analysis. Future development to be assessed post final results review.

Analysts Question Commercial Viability of Marinus&#39; IV Ganaxolone After Interim Analysis Miss

Earnings

Eurozone

Commodities

Small Cap

Global

Intraday Update

LGVN

NMRA

RARE

SNGX

SNPO

U.S. stocks turned lower toward the end of trading, with the S&amp;P 500 falling more than 1% on Monday.

The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&amp;P 500 also fell, dropping, 1.14% to 5,065.04.

S&amp;P 500 Down Over 1%; US Retail Sales Increase 0.7% In March

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharmaceuticals Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. cut the price target for Unity Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ubx#NASDAQ">UBX</a>) from $10 to $8. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Unity Biotechnology shares gained 1.3% to close at $1.52 on Tuesday. <a href="https://www.benzinga.com/quote/UBX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen slashed the price target for Amgen Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amgn#NASDAQ">AMGN</a>) from $370 to $360. TD Cowen analyst Yaron Weber maintained the stock with a Buy rating. Amgen shares rose 0.1% to close at $265.64 on Tuesday. <a href="https://www.benzinga.com/quote/AMGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) price target from $180 to $170. B of A Securities analyst Geoff Meacham maintained a Neutral rating. Johnson &amp; Johnson shares fell 2.1% to close at $144.45 on Tuesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for Antero Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ar#NYSE">AR</a>) from $26 to $36. Morgan Stanley analyst Devin McDermott upgraded the stock from Equal-Weight to Overweight. Antero Resources shares gained 0.4% to close at $29.12 on Tuesday. <a href="https://www.benzinga.com/quote/AR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. slashed J.B. Hunt Transport Services, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jbht#NASDAQ">JBHT</a>) price target from $210 to $192. Stephens &amp; Co. analyst Justin Long maintained an Overweight rating. J.B. Hunt Transport shares fell 1.1% to close at $182.99 on Tuesday. <a href="https://www.benzinga.com/quote/JBHT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities raised Strategic Education, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stra#NASDAQ">STRA</a>) price target from $110 to $125. Truist Securities analyst Tobey Sommer upgraded the stock from Hold to Buy. Strategic Education shares fell 0.6% to close at $96.71 on Tuesday. <a href="https://www.benzinga.com/quote/STRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies lowered the price target for Urban Outfitters, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/urbn#NASDAQ">URBN</a>) from $42 to $32. Jefferies analyst Corey Tarlowe downgraded the stock from Hold to Underperform. Urban Outfitters shares fell 0.5% to close at $38.02 on Tuesday. <a href="https://www.benzinga.com/quote/URBN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital cut Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) price target from $24 to $3. RBC Capital analyst Brian Abrahams downgraded the stock from Outperform to Sector Perform. Marinus Pharmaceuticals shares fell 7.7% to close at $1.20 on Tuesday. <a href="https://www.benzinga.com/quote/MRNS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Visa Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/v#NYSE">V</a>) price target from $314 to $320. Baird analyst David Koning maintained an Outperform rating. Visa shares rose 0.1% to close at $271.35 on Tuesday. <a href="https://www.benzinga.com/quote/V/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised The Bank of New York Mellon Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bk#NYSE">BK</a>) price target from $64 to $66. B of A Securities analyst Ebrahim Poonawala maintained a Buy rating. Bank of New York Mellon shares fell 2% to close at $54.00 on Tuesday. <a href="https://www.benzinga.com/quote/BK/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/24/04/38286501/why-invo-bioscience-shares-are-trading-higher-by-around-73-here-are-20-stocks-moving-premarket"> Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket </a>

RBC Capital analyst Brian Abrahams downgrades Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) from Outperform to Sector Perform and lowers the price target from $24 to $3.

RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3

Monday, in an interim analysis of&nbsp;Marinus Pharmaceuticals Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) phase 3 RAISE trial, evaluating intravenous (IV) ganaxolone as a treatment for refractory status epilepticus (RSE), failed to meet pre-defined &#8220;stopping criteria.&#8221;
Marinus has completed RAISE enrollment at approximately 100 patients, with topline results expected&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38249505/why-did-epilepsyseizure-focused-marinus-pharmaceuticals-stock-hit-52-week-low-on-monday" rel="noreferrer noopener">in the summer of 2024</a>.
The company said the future development of IV ganaxolone in refractory status epilepticus will be assessed following a review of the final RAISE study results.
An independent Data Monitoring Committee (DMC) recommended continuing the study.
Cantor Fitzgerald&nbsp;said it shifted focus to oral ganaxolone (O-GNX), which is progressing in the global Phase 3 TrustTSC study for tuberous sclerosis complex (TSC), and to a second-generation ganaxolone (2G-O-GNX) formulation aimed at enhancing safety, efficacy, and tolerability, potentially enabling less frequent dosing.
The analyst anticipates that further data analysis, once the study is complete, may provide clarity on statistical significance, but the potential commercial viability of IVGNX may be the &#8220;trump card&#8221; decision driver.
The analyst maintains the Overweight rating with a reduced&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/MRNS/analyst-ratings" rel="noreferrer noopener">price target of $13 from $28</a>.
RBC Capital Markets&nbsp;says the IV ganaxolone study update is disappointing and somewhat surprising given prior data and a careful study design albeit in a challenging indication.&nbsp;
That said, capital constraints are placing more pressure on the upcoming Phase 3 TSC readout, and RBC views that the TSC study is a higher risk and &lt;50/50 to hit; it is difficult to recommend buying ahead of that.&nbsp;
RBC downgraded to Sector Perform from Outperform, with a price target of $3, down from a prior target of $24.
Price Action: MRNS shares are down 8.07% at $1.1950 on the last check Tuesday.
Photo via Darko Stojanovic from Pixabay

Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss

Ratings for Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $20.71, a high estimate of $28.00, and a low estimate of $3.00. Marking an increase of 25.52%, the current average surpasses the previous average price target of $16.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1713286819_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Marinus Pharma by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$3.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Perform</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Marinus Pharma. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Marinus Pharma compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Marinus Pharma's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Marinus Pharma's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Marinus Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Marinus Pharma: A Closer Look</h2>
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
<h3>Unraveling the Financial Story of Marinus Pharma</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Marinus Pharma's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 0.39%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Marinus Pharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -580.93% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Marinus Pharma's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -117.16%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -22.47%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 4.4, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Marinus Pharma

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) with a Buy and maintains $27 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target

U.S. stocks turned lower toward the end of trading, with the S&amp;P 500 falling more than 1% on Monday.
The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&amp;P 500 also fell, dropping, 1.14% to 5,065.04.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38218786/best-buy-box-and-2-other-stocks-insiders-are-selling"> Best Buy, Box And 2 Other Stocks Insiders Are Selling </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Health care shares rose by 0.01% on Friday.
In trading on Friday, information technology shares fell by 1.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
U.S. retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares shot up 34% to $0.5197 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
Shares of Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) got a boost, surging 58% to $2.6750 following insider buys from multiple company executives.
Snap One Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpo#NASDAQ">SNPO</a>) shares were also up, gaining 30% to $10.60 after the company announced that it will be acquired by Resideo Technologies.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dropped 81% to $1.4250 after the company provided an update on the Phase 3 RAISE trial and reported preliminary first-quarter financial results.
Shares of Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) were down 11% to $12.02 after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.
Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) was down, falling 10% to $42.73 after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Also Check This Out:<a href="https://www.benzinga.com/news/24/04/38246593/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Tech Stocks With Over 4% Dividend Yields </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.6% to $85.17 while gold traded up 0.3% at $2,381.50.
Silver traded up 1.6% to $28.795 on Friday, while copper rose 2.3% to $4.3575.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.13%, London&rsquo;s FTSE 100 fell 0.38% while Spain&rsquo;s IBEX 35 Index rose 0.01% The German DAX gained 0.54% French CAC 40 climbed 0.43% while Italy&rsquo;s FTSE MIB Index jumped 0.56%.
Industrial production in the eurozone increased by 0.8% month-over-month in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Monday, with Japan&rsquo;s Nikkei 225 falling 0.74%, Hong Kong&rsquo;s Hang Seng Index dropping 0.72%, China&rsquo;s Shanghai Composite gaining 1.26% and India&rsquo;s S&amp;P BSE Sensex dipping 1.14%.
Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month&rsquo;s reading of -20.9.
Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.
The NAHB/Wells Fargo Housing Market Index in came in unchanged at 51.0 in April.
Total business inventories increased by 0.4% month-over-month in February, versus market expectations of a 0.3% rise.
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38248683/bitcoin-surpasses-66-000-core-emerges-as-top-gainer"> Bitcoin Surpasses $66,000; Core Emerges As Top Gainer </a>
&nbsp;

S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) fell sharply during Monday&rsquo;s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.</li>
<li>Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) surged 54% to $2.6350 following insider buys from multiple company executives.</li>
<li>SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) shares gained 39.4% to $0.3849 after jumping around 18% on Friday.</li>
<li>Piedmont Lithium Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pll#NYSE">PLL</a>) shares gained 32.1% to $16.75 following a 5% decline on Friday.</li>
<li>Snap One Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpo#NASDAQ">SNPO</a>) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies.</li>
<li>Organovo Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.</li>
<li>Kuke Music Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kuke#NASDAQ">KUKE</a>) jumped 27% to $2.7650.</li>
<li>HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) gained 24% to $1.61 after gaining over 11% on Friday.</li>
<li>Edgio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egio#NASDAQ">EGIO</a>) gained 24% to $22.18.</li>
<li>Kaival Brands Innovations Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kavl#NASDAQ">KAVL</a>) surged 23.6% to $3.30.</li>
<li>Envoy Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coch#NASDAQ">COCH</a>) gained 22.6% to $6.19.</li>
<li>Medical Properties Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpw#NYSE">MPW</a>) rose 19.9% to $4.7850 after the company announced that it sold its majority interest in Utah Hospitals.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) climbed 19.5% to $3.78.</li>
<li>SES AI Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ses#NYSE">SES</a>) surged 18.7% to $1.77.</li>
<li>Mobile-health Network Solutions (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mndr#NASDAQ">MNDR</a>) gained 17.7% to $17.67.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) rose 16.7% to $2.72.</li>
<li>ProKidney Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prok#NASDAQ">PROK</a>) gained 16.7% to $2.0426.</li>
<li>Biotricity, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btcy#NASDAQ">BTCY</a>) rose 16.5% to $1.34.</li>
<li>Yatsen Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ysg#NYSE">YSG</a>) gained 13.3% to $3.41.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) shares gained 12.8% to $32.71 after dipping 42% on Friday.</li>
<li>Encore Wire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wire#NASDAQ">WIRE</a>) surged 11.7% to $291.60 after the company entered an agreement to be acquired by Prysmian for $290 per share in cash.</li>
<li>Century Aluminum Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cenx#NASDAQ">CENX</a>) gained 9.5% to $18.05.</li>
<li>Extreme Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/extr#NASDAQ">EXTR</a>) gained 5.7% to $11.31. B. Riley Securities analyst Dave Kang upgraded Extreme Networks from Neutral to Buy and maintained a $14 price target.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dipped 77% to $1.6800 after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.</li>
<li>Swvl Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) fell 35% to $8.58.</li>
<li>VIA optronics AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viao#NASDAQ">VIAO</a>) dipped 34% to $0.2765.</li>
<li>Veru Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/veru#NASDAQ">VERU</a>) fell 24% to $1.1550. Oppenheimer analyst Leland Gershell reiterated Veru with an Outperform and lowered the price target from $7 to $5.</li>
<li>Rent the Runway, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rent#NASDAQ">RENT</a>) dipped 19.8% to $15.42.</li>
<li>NextPlat Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxpl#NASDAQ">NXPL</a>) fell 19.8% to $1.50 after jumping 24% on Friday. The company entered into a definitive business combination agreement with its majority-owned subsidiary Progressive Care Inc.</li>
<li>Cyngn Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyn#NASDAQ">CYN</a>) shares fell 19.1% to $0.1170 after declining around 7% on Friday.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) fell 15.6% to $1.95.</li>
<li>Biohaven Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bhvn#NASDAQ">BHVN</a>) dipped 15.4% to $44.90. Biohaven showcased innovative neuroscience portfolio with 20 presentations at the 2024 AAN Annual Meeting.</li>
<li>Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) shares declined 15.1% to $11.48 after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.</li>
<li>Alterity Therapeutics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athe#NASDAQ">ATHE</a>) dipped 15% to $2.49.</li>
<li>Surf Air Mobility Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srfm#NASDAQ">SRFM</a>) fell 15% to $0.53.</li>
<li>IM Cannabis Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imcc#NASDAQ">IMCC</a>) fell 14.2% to $0.5399.</li>
<li>Polestar Automotive Holding Uk Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) fell 12.7% to $1.2699. On Friday, Cantor Fitzgerald analyst Andres Sheppard reiterated Polestar Automotive with an Overweight and maintained a $5 price target.</li>
<li>Desktop Metal, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dm#NYSE">DM</a>) fell 10.8% to $0.8510.</li>
<li>Local Bounti Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/locl#NYSE">LOCL</a>) declined 10.2% to $2.1550.</li>
<li>Q32 Bio Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qttb#NASDAQ">QTTB</a>) fell 10% to $26.00.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) fell 8.3% to $2.2750.</li>
<li>Informatica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/infa#NASDAQ">INFA</a>) dipped 8.1% to $35.36 amid increased volatility following reports suggesting Salesforce is in talks to buy the company.</li>
<li>TRACON Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) declined 8.1% to $2.1699 after falling around 9% on Friday.</li>
<li>NOVONIX Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvx#NYSE">NVX</a>) declined 7.2% to $2.63.</li>
<li>AudioEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeye#NASDAQ">AEYE</a>) fell 6.6% to $12.86 after declining around 7% on Friday.</li>
<li>OncoCyte Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocx#NASDAQ">OCX</a>) fell 6.6% to $2.5301. Oncocyte announced a transplant assay partnership agreement with Bio-Rad laboratories.</li>
<li>BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) fell 6.1% to $2.8650.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38249138/dow-jumps-over-300-points-goldman-sachs-posts-upbeat-earnings"> Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings</a>

Movers

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LOCL

MNDR

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

ONVO

PROK

PSNY

QTTB

RENT

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock moved upwards by 44.4% to $2.44 during Monday's regular session. The market value of their outstanding shares is at $7.7 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares rose 35.53% to $20.33. The company's market cap stands at $691.2 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares moved upwards by 31.89% to $0.12. The company's market cap stands at $32.8 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock increased by 30.35% to $0.5. The market value of their outstanding shares is at $5.2 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock increased by 26.33% to $2.21. The company's market cap stands at $136.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares moved upwards by 24.58% to $1.26. The market value of their outstanding shares is at $12.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares fell 79.8% to $1.52 during Monday's regular session. The market value of their outstanding shares is at $83.4 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock decreased by 20.07% to $2.35. The company's market cap stands at $20.5 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock decreased by 18.76% to $1.1. The market value of their outstanding shares is at $10.3 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares fell 18.16% to $1.8. The market value of their outstanding shares is at $74.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock fell 17.42% to $0.94. The market value of their outstanding shares is at $13.9 million. As per the news, the Q4 earnings report came out today. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock declined by 17.15% to $1.16. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

JAGX

LIFW

RLYB

SXTC

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday.
The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&amp;P 500 also rose, gaining, 0.26% to 5,136.94.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38218786/best-buy-box-and-2-other-stocks-insiders-are-selling"> Best Buy, Box And 2 Other Stocks Insiders Are Selling </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Health care shares jumped by 0.7% on Friday.
In trading on Friday, real estate shares fell by 1.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Charles Schwab Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/schw#NYSE">SCHW</a>) reported better-than-expected first-quarter earnings on Monday.
Charles Schwab reported a first-quarter 2024 adjusted net income decline of 17% Y/Y to $1.469 billion. Adjusted EPS fell 20% Y/Y to 74 cents, which came in line with the consensus. Revenue fell 7% to $4.74 billion, marginally beating the consensus of $4.71 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares shot up 49% to $0.5802 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
Shares of Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) got a boost, surging 52% to $2.5650 following insider buys from multiple company executives.
Snap One Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpo#NASDAQ">SNPO</a>) shares were also up, gaining 30% to $10.61 after the company announced that it will be acquired by Resideo Technologies.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dropped 79% to $1.5792 after the company provided an update on the Phase 3 RAISE trial and reported preliminary first-quarter financial results.
Shares of Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) were down 14% to $11.67 after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.
Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) was down, falling 10% to $42.46 after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Also Check This Out:<a href="https://www.benzinga.com/news/24/04/38246593/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Tech Stocks With Over 4% Dividend Yields </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 1.3% to $84.55 while gold traded down 0.5% at $2,362.00.
Silver traded up 0.8% to $28.55 on Friday, while copper rose 1.7% to $4.3315.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.06%, London&rsquo;s FTSE 100 fell 0.48% while Spain&rsquo;s IBEX 35 Index fell 0.11% The German DAX gained 0.39% French CAC 40 climbed 0.31% while Italy&rsquo;s FTSE MIB Index jumped 0.45%.
Industrial production in the eurozone increased by 0.8% month-over-month in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Monday, with Japan&rsquo;s Nikkei 225 falling 0.74%, Hong Kong&rsquo;s Hang Seng Index dropping 0.72%, China&rsquo;s Shanghai Composite gaining 1.26% and India&rsquo;s S&amp;P BSE Sensex dipping 1.14%.
Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month&rsquo;s reading of -20.9.
Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.
The NAHB/Wells Fargo Housing Market Index in came in unchanged at 51.0 in April.
Total business inventories increased by 0.4% month-over-month in February, versus market expectations of a 0.3% rise.
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38248683/bitcoin-surpasses-66-000-core-emerges-as-top-gainer"> Bitcoin Surpasses $66,000; Core Emerges As Top Gainer </a>

SCHW

Crude Oil Down 1%; Charles Schwab Sales Top Estimates

Monday,&nbsp;Marinus Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38244790/marinus-pharmaceuticals-provides-update-on-the-phase-3-raise-trial-and-reports-preliminary-first-q" rel="noreferrer noopener">an interim analysis</a>.
Marinus has decided to complete enrollment in the RAISE trial at approximately 100 patients, with topline results expected in the summer of 2024.&nbsp;
The results will be used to determine whether to continue the development of IV ganaxolone. Marinus remains blinded to the RAISE trial data.
&#8220;While we are disappointed that RAISE did not meet the early stopping criteria, we will only be able to determine the trial&#8217;s outcome once we unblind and analyze the full data set,&#8221; said Scott Braunstein, Chairman and Chief Executive Officer of Marinus. &#8220;We will also be evaluating potential cost-saving strategies to provide the strongest capital position as we approach enrollment completion in the global Phase 3 TrustTSC trial in tuberous sclerosis complex.&#8221;
Marinus expects to complete enrollment in the Phase 3 TrustTSC trial of Ztalmy (ganaxolone) oral suspension CV with approximately 130 patients in mid-May 2024.&nbsp;
The company expects topline results early in the fourth quarter of 2024 and anticipates filing a supplemental New Drug Application to the FDA in the first half of 2025 with a request for priority review.
Marinus also continues developing a second-generation ganaxolone formulation intended to provide improved pharmacodynamic and pharmacokinetic profiles that improve safety, efficacy, and tolerability and enable less frequent dosing.
The company continues the U.S. commercial launch of Ztalmy, resulting in preliminary unaudited net product revenue of between $7.4 and $7.6 million for the first quarter of 2024.&nbsp;
Marinus estimates preliminary unaudited cash, cash equivalents, and short-term investments of $113.3 million as of March 31, 2024. Cost reduction activities to extend the cash runway beyond the fourth quarter of 2024 are under review and are expected to be implemented in the current quarter.
Price Action:&nbsp;MRNS shares are down 77.30% at $1.71 on the last check Monday.

Biotech

Health Care

General

Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday.
The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&amp;P 500 also rose, gaining, 0.80% to 5,164.30.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38218786/best-buy-box-and-2-other-stocks-insiders-are-selling"> Best Buy, Box And 2 Other Stocks Insiders Are Selling </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Financial shares jumped by 1.5% on Friday.
In trading on Friday, real estate shares rose by just 0.3%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Goldman Sachs Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>) reported better-than-expected first-quarter earnings on Monday.
Goldman Sachs reported revenue of $14.21 billion for the first quarter of 2024, beating the consensus of $12.92 billion. The U.S. financial services giant reported EPS of $11.58, beating the consensus of $8.60.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares shot up 98% to $0.7699 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
Shares of Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) got a boost, surging 70% to $2.87 following insider buys from multiple company executives.
Organovo Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) shares were also up, gaining 23% to $1.2613 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dropped 76% to $1.7680 after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.
Shares of ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) were down 29% to $1.63.
PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) was down, falling 23% to $0.6501. PaxMedica, last week, announced the completed execution of three pivotal registration/validation batches of PAX-101.
Also Check This Out:<a href="https://www.benzinga.com/news/24/04/38246593/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Tech Stocks With Over 4% Dividend Yields </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.5% to $85.43 while gold traded down 0.8% at $2,353.50.
Silver traded down 0.6% to $28.075 on Friday, while copper rose 0.1% to $4.2580.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were higher today. The eurozone&rsquo;s STOXX 600 rose 0.8%, London&rsquo;s FTSE 100 gained 0.1% while Spain&rsquo;s IBEX 35 Index rose 0.6% The German DAX gained 1.4% French CAC 40 climbed 1.3% while Italy&rsquo;s FTSE MIB Index jumped 1.5%.
Industrial production in the eurozone increased by 0.8% month-over-month in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Monday, with Japan&rsquo;s Nikkei 225 falling 0.74%, Hong Kong&rsquo;s Hang Seng Index dropping 0.72%, China&rsquo;s Shanghai Composite gaining 1.26% and India&rsquo;s S&amp;P BSE Sensex dipping 1.14%.
Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month&rsquo;s reading of -20.9.
Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38248683/bitcoin-surpasses-66-000-core-emerges-as-top-gainer"> Bitcoin Surpasses $66,000; Core Emerges As Top Gainer </a>

PXMD

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings

WIIM

Marinus Pharmaceuticals shares are trading lower after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Shares of Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) fell sharply in today&rsquo;s pre-market trading after the company issued an update on the Phase 3 RAISE Trial and reported preliminary first <a href="https://www.benzinga.com/quote/MRNS">quarter 2024 financial results</a>.
Marinus Pharma reported Prelim ZTALMY (Ganaxolone) net product revenue of $7.4 million to $7.6 million for the first quarter.
Marinus Pharmaceuticals shares dipped 74.2% to $1.94in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) shares declined 17.1% to $11.25 pre-market trading after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.</li>
<li>Roadzen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdzn#NASDAQ">RDZN</a>) shares fell 14% to $5.04 in pre-market trading.</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) shares fell 11.4% to $41.64 in pre-market trading after the company disclosed interim Phase 1/2 data in patients with angelman syndrome after treatment with GTX-102.</li>
<li>Cogent Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cogt#NASDAQ">COGT</a>) shares declined 7.7% to $6.01 in pre-market trading. Cogent Biosciences recently reported preclinical data from CNS-Penetrant ErbB2 Inhibitor Program.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) shares fell 7.2% to $1.35 in pre-market trading.</li>
<li>Molina Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/moh#NYSE">MOH</a>) shares fell 7.1% to $350.00 in pre-market trading.</li>
<li>TORM plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trmd#NASDAQ">TRMD</a>) shares slipped 3.1% to $32.92 in pre-market trading.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38244618/top-3-tech-stocks-that-may-explode-this-month"> Top 3 Tech Stocks That May Explode This Month</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Pre-Market Outlook

COGT

RDZN

TRMD

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock increased by 95.1% to $0.75 during Monday's pre-market session. The company's market cap stands at $7.9 million. </li>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares increased by 51.47% to $2.56. The company's market cap stands at $8.1 million. </li>
<li>Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) shares moved upwards by 40.02% to $27.15. The company's market cap stands at $482.7 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares rose 21.98% to $1.01. The company's market cap stands at $16.9 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares increased by 21.42% to $2.55. The company's market cap stands at $1.2 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock moved upwards by 18.81% to $6.0. The company's market cap stands at $117.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 74.5% to $1.92 during Monday's pre-market session. The market value of their outstanding shares is at $105.4 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares decreased by 17.8% to $1.94. The market value of their outstanding shares is at $4.4 million. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) shares declined by 17.04% to $11.25. The company's market cap stands at $1.7 billion. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) stock fell 16.57% to $0.7. The market value of their outstanding shares is at $5.1 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock fell 15.65% to $2.48. The market value of their outstanding shares is at $21.6 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares decreased by 15.19% to $0.02. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

BMRA

RNAC

SINT

12 Health Care Stocks Moving In Monday's Pre-Market Session

The Company continues the successful U.S. commercial launch of ZTALMY&nbsp;resulting in preliminary unaudited net product revenue of between&nbsp;$7.4&nbsp;and&nbsp;$7.6 million&nbsp;for the&nbsp;first quarter&nbsp;of 2024. Marinus estimates preliminary unaudited cash, cash equivalents, and short-term investments of&nbsp;$113.3 million&nbsp;as of March&nbsp;31, 2024.

Marinus Pharma Reported Prelim ZTALMY (Ganaxolone) Q1 Net Product Revenue of $7.4M-$7.6M, Cash of $113.3M

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.marinuspharma.com%2F&amp;esheet=53929454&amp;newsitemid=20240415026329&amp;lan=en-US&amp;anchor=Marinus+Pharmaceuticals&amp;index=1&amp;md5=b17023d4c63a484e02a8a4313f0a0ce9">Marinus Pharmaceuticals</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis.
Marinus has decided to complete enrollment in the RAISE trial at approximately 100 patients with topline results expected in the summer of 2024. Those results will be used to determine whether to continue development of IV ganaxolone. Marinus remains blinded to the RAISE trial data.
&quot;While we are disappointed that RAISE did not meet the early stopping criteria, we will only be able to determine the trial&#39;s outcome once we unblind and analyze the full data set,&quot; said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. &quot;We will also be evaluating potential cost-saving strategies to provide the strongest capital position as we approach enrollment completion in the global Phase 3 TrustTSC trial in tuberous sclerosis complex.&quot;
Ganaxolone development in the RAISE trial is being supported in part by the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under contract number 75A50120C00159.
General Business and Financial Update
Marinus expects to complete enrollment in the Phase 3 TrustTSC trial of ZTALMY&reg;&nbsp;(ganaxolone) oral suspension CV with approximately 130 patients in mid-May 2024. The Company expects topline results early in the&nbsp;fourth quarter&nbsp;of 2024 and anticipates filing a supplemental New Drug Application to the U.S. Food and Drug Administration in the first half of 2025 with a request for priority review.
Marinus also continues to develop a second-generation ganaxolone formulation intended to provide improved pharmacodynamic and pharmacokinetic profiles that could improve safety, efficacy and tolerability and enable less frequent dosing.
The Company continues the successful U.S. commercial launch of ZTALMY resulting in preliminary unaudited net product revenue of between&nbsp;$7.4&nbsp;and&nbsp;$7.6 million&nbsp;for the&nbsp;first quarter&nbsp;of 2024. Marinus estimates preliminary unaudited cash, cash equivalents, and short-term investments of&nbsp;$113.3 million&nbsp;as of March 31, 2024. Cost reduction activities to extend the cash runway beyond the&nbsp;fourth quarter&nbsp;of 2024 are under review and are expected to be implemented in the current quarter.

Marinus Pharma to Continue Phase 3 RAISE Trial of IV Ganaxolone for Severe Seizure Treatment, Advances with ZTALMY's Successful Launch, Eyes New Drug Application and Optimizes Cash Runway

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Cantor Fitzgerald analyst Charles Duncan reiterates Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) with a Overweight and maintains $28 price target.

Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Stocks are up today and investors wondering what&rsquo;s behind that rally have come to the right place as we have the latest news for Monday!



Stocks are up today as <a href="https://finance.yahoo.com/news/retail-sales-topped-wall-street-estimates-in-march-124009661.html">retail data came in better than expected</a>. The data saw retail sales in March increase by .7%, as compared to the .4% increase that Wall Street was expecting.



To go along with that, the retail sales data for February was revised in the latest report. This bumped it up to a .9% increase from the previous report of a .6% increase.



In addition to that is a strong earnings report from Goldman Sachs (NYSE:<a href="https://investorplace.com/stock-quotes/gs-stock-quote/">GS</a>). The financial firm saw its profits rise higher during its most recent quarter. This has net income for the period <a href="https://finance.yahoo.com/news/profits-surge-at-goldman-sachs-on-wall-street-revival-112940260.html">sitting at $4.1 billion</a>.



Let&rsquo;s check out how all of this news is affecting <a href="https://finance.yahoo.com/world-indices/">the major indices</a> below!



<h2>Stocks Up Today: Major Indices Rally</h2>



<ul><li>The S&amp;P 500 starts us off with a .31% increase as of noon Monday.</li>



<li>Next we have the Dow Jones Industrial Average with a .39% rise as of this writing.</li>



<li>Closing us out is the NASDAQ Composite with a .1% gain today.</li>
</ul>Investors who are seeking out even more of the most recent stock market stories are going to want to stick around!



We are offering up all of the hottest stock market news that traders need to know about on Monday! A few examples include what&rsquo;s going on with shares of Trump Media &amp; Technology&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/djt-stock-quote/">DJT</a>), Marinus Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mrns-stock-quote/">MRNS</a>) and Soligenix&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) stock today. All of that info is ready to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/djt-stock-alert-trump-media-plunges-on-share-sale-panic/">DJT Stock Alert: Trump Media Plunges on Share Sale Panic</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-marinus-pharmaceuticals-mrns-stock-down-79-today/">Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-soligenix-sngx-stock-up-58-today/">Why Is Soligenix (SNGX) Stock Up 58% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-are-stocks-up-today-april-15th/">Why Are Stocks Up Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Are Stocks Up Today?

BSGM, ENLV and WISA among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result. And poor results can happen to anybody, big or small.



Indeed, the prospect of being on the wrong end of a giant killing adds significant risk to market participants. So, as a calculated approach, since you&rsquo;re going to be taking huge risks anyways, you might as well go for ideas with the substantial upside return potential. On that note, below are under-$10 biotech stocks to consider.



<h2>Actinium Pharmaceuticals (ATNM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Based in New York, Actinium Pharmaceuticals (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/atnm-stock-quote/">ATNM</a>) is a clinical-stage biopharmaceutical company <a href="https://finance.yahoo.com/quote/ATNM/profile">developing targeted radiotherapies</a>. Specifically, it delivers cancer-killing radiation to treat patients with high unmet medical needs. Actinium features a product candidate which is in Phase 3 clinical trials for elderly relapsed or refractory acute myeloid leukemia.



Currently, Wall Street analysts rate ATNM a <a href="https://www.tipranks.com/stocks/atnm/forecast">unanimous strong buy</a>. Their average price target stands at $30.50, implying nearly 239% upside potential. Notably, the high-side estimate calls for a price of $50. Among the covering experts, they&rsquo;re anticipating fiscal 2024 loss per share to land at $1.73. Though not profitable, this forecast represents an improvement over last year&rsquo;s loss of $1.83.



At the moment, Actinium is practically a pre-revenue enterprise. If we want to dive into the minutia, it did post sales of $81,000 last year. However, it&rsquo;s not projected to generate any sales this year. However, in fiscal 2025, analysts are looking for sales of $72.82 million. Therefore, it&rsquo;s one of the more promising ideas for under-$10 biotech stocks to consider.



<h2>Outlook Therapeutics (OTLK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/eyes-stock-1-300x169.png" alt="Image of a woman with a digital display over her eye."><div>Source: Who is Danny / Shutterstock.com</div></div>Headquartered in Iselin, New Jersey, Outlook Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/otlk-stock-quote/">OTLK</a>) operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate, <a href="https://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeuticsr-receives-european-union-positive-chmp#:~:text=ONS%2D5010%2FLYTENAVA%E2%84%A2%20is,AMD%20and%20other%20retinal%20diseases.">ONS-5010 for the treatment of wet age-related macular degeneration</a> and other retina diseases is currently in Phase 3 clinical trials.



Presently, Wall Street rates OTLK a <a href="https://www.tipranks.com/stocks/otlk/forecast">unanimous strong buy</a>. Further, the average price target lands at $40.20, implying 362% growth potential. Moreover, the highest price target hits $60, emphasizing the broad enthusiasm for this biotech firm. For fiscal 2024, experts see the company posting a loss per share of $3.28. Yes, it&rsquo;s in the red but it&rsquo;s an improvement over last year&rsquo;s $4.80 below breakeven.



However, the top line is where things get exciting. Analysts see revenue reaching $240,000, with the high-side estimate hitting $1.43 million. Last year, Outlook did not generate any sales. Even better, forecasts call for fiscal 2025 sales to hit $13.09 million. Thus, it&rsquo;s a compelling idea for under-$10 biotech stocks.



<h2>Recursion Pharmaceuticals (RXRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/rxrx1600-300x169.png" alt="Recursion Pharmaceuticals (RXRX) website displayed on a modern smartphone"><div>Source: Piotr Swat / Shutterstock.com</div></div>A clinical-stage biotech firm, Recursion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rxrx-stock-quote/">RXRX</a>) engages in integrating technological innovations across biology, automation, data science and engineering to industrialize drug discovery. One of its lead product candidates, a therapeutic for treating cerebral cavernous malformation, is currently in Phase 2 clinical trials.



Per analysts, RXRX stock represents a <a href="https://www.tipranks.com/stocks/rxrx/forecast">moderate buy</a>. Further, the average price target lands at $17, implying over 102% upside potential. For the current fiscal year, experts anticipate Recursion to post a loss per share of $1.72. Admittedly, that&rsquo;s worse than last year&rsquo;s red ink of $1.58. That said, the most optimistic assessment calls for a loss of $1.49.



On the top line, the news becomes substantially more favorable. Analysts are looking for sales of $56.16 million,. That would be up 26% from last year&rsquo;s tally of $44.58 million. For fiscal 2025, they&rsquo;re looking for revenue of $88.43 million, up 57.5% against projected 2024 sales. If you like to speculate, RXRX belongs on your radar of under-$10 biotech stocks to buy.



<h2>Ocular Therapeutix (OCUL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/eye-1600-300x169.jpg" alt="A close-up of someone's eye"><div>Source: Shutterstock</div></div>Headquartered in Bedford, Massachusetts, Ocular Therapeutix (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocul-stock-quote/">OCUL</a>) is a biopharma company focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye. It uses a bioresorbable hydrogel-based formulation technology. It&rsquo;s developing an <a href="https://www.ophthalmologytimes.com/view/ocular-therapeutix-inc-screens-first-3-patients-in-phase-3-sol-1-trial">axitinib intravitreal implant that is in Phase 3 trials</a> for the treatment of wet age-related macular degeneration.



Per Wall Street analysts, OCUL rates as a <a href="https://www.tipranks.com/stocks/ocul/forecast">consensus strong buy</a>. On average, the price target stands at $16.33, implying over 104% upside potential. Further, the most optimistic target calls for a price of $24. Covering experts see fiscal 2024&rsquo;s loss per share coming in at 83 cents. While not a profitable enterprise, this figure would represent a conspicuous improvement over last year&rsquo;s loss of $1.02.



On the top line, analysts anticipate revenue to hit $68.34 million. If so, we&rsquo;re talking about year-over-year growth of 16.9% from last year&rsquo;s haul of $58.44 million. For fiscal 2025, they&rsquo;re looking for sales of $85.9 million. Even better, the highest target seeks a top-line print of $116 million. Overall, it&rsquo;s a compelling take for under-$10 biotech stocks.



<h2>Marinus (MRNS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>Based in Radnor, Pennsylvania, Marinus (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrns-stock-quote/">MRNS</a>) is a pharmaceutical company focusing on the development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. Its <a href="https://ir.marinuspharma.com/news/news-details/2024/Marinus-Pharmaceuticals-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2023-ZTALMY-Net-Product-Revenue-and-Provides-Business-Update/default.aspx">main product is Ztalmy</a>, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations.



Presently, covering experts rate MRNS stock as a <a href="https://www.tipranks.com/stocks/mrns/forecast#">consensus strong buy</a>. The average price target lands at $19.78, implying 163% growth potential. Also, the highest target calls for a price per share of $28. For the current fiscal year, analysts are looking for a loss per share of $2.36. While the bottom line is printed in red ink, the projected figure would be an improvement over last year&rsquo;s loss of $2.63 per share.



On the top line, analysts are looking for revenue of $40.53 million. That would imply YOY growth of nearly 31% from last year&rsquo;s haul of $30.99 million. Further, the most optimistic target seeks a sales print of $54.3 million. For fiscal 2025, revenue could rise to $66.62 million. Based on the growth potential, MRNS is one of the under-$10 biotech stocks to consider.



<h2>Fulcrum Therapeutics (FULC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div>Calling Cambridge, Massachusetts home, Fulcrum Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/fulc-stock-quote/">FULC</a>) is a clinical-stage biopharma focusing on the development of products for improving the lives of patients suffering from genetically defined diseases. In particular, it seeks to address conditions with high unmet medical needs. It features a small-molecule-based candidate that&rsquo;s in Phase 3 trials for the treatment of muscular dystrophy.



Presently, Wall Street analysts rate FULC a <a href="https://www.tipranks.com/stocks/fulc/forecast">consensus strong buy</a> with a $13.29 average price target. That implies over 77% upside potential. Further, the most optimistic forecast calls for a price per share of $17. For fiscal 2024, covering experts are anticipating a loss per share of $1.75. Admittedly, that&rsquo;s an expansion of last year&rsquo;s red ink of $1.59 per share.



It also doesn&rsquo;t immediately get better on the top line, with analysts projecting sales of $1.92 million. Conspicuously, that&rsquo;s 31.6% off the pace of last year&rsquo;s tally of $2.81 million. Still, the focal point is on fiscal 2025&rsquo;s projected sales of $13.34 million. Further, the high-side estimate lands at $42.88 million. Therefore, for the patient speculator, FULC could be one of the under-$10 biotech stocks to buy.



<h2>CorMedix (CRMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div>Headquartered in Berkeley Heights, New Jersey, CorMedix (NASDAQ:<a href="https://investorplace.com/stock-quotes/crmd-stock-quote/">CRMD</a>) is a biopharma firm focusing on the development and commercialization of therapeutic products in the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate is <a href="https://cormedix.com/cormedix-inc-announces-commercial-and-operational-updates/">DefenCath, an antimicrobial catheter lock solution</a> to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.



Although it&rsquo;s one of the riskiest under-$10 biotech stocks, it also enjoys plenty of love on the Street. Analysts rate shares a unanimous strong buy with a $12.67 price target. That implies upside potential of just under 117%. Also, the high-side target hits $19.



For fiscal 2024, experts are looking at a loss per share of 74 cents. That&rsquo;s still in the red but an improvement over last year&rsquo;s loss of 91 cents. On the top line, they&rsquo;re seeking $25.16 million. Last year, the company generated no revenue. Finally, for fiscal 2025, experts are seeking sales of $81.93 million, implying 225.6% YOY growth from projected 2024 revenue.



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/biotech-on-a-budget-7-stocks-under-10-with-huge-potential/">Biotech on a Budget: 7 Stocks Under $10 With Huge Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Marinus (MRNS – Research Report) and decreased the price target to $12.00 from ...

Maintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial Health

Analyst Michael Higgins of Ladenburg Thalmann & Co. maintained a Buy rating on Marinus (MRNS – Research Report), reducing the price target to $4.00...

Marinus Pharmaceuticals: A Strong Buy Despite RAISE Trial Setback, with Promising Growth Potential in DEE Market

Robert W. Baird analyst Brian Skorney downgraded the rating on Marinus (MRNS – Research Report) to a Hold today, setting a price target of $2.00. B...

Maintaining Hold on Marinus Amid Clinical Setbacks and Uncertain Financial Outlook

Oppenheimer analyst Jay Olson maintained a Hold rating on Marinus (MRNS – Research Report) today. The company's shares closed yesterday at $1.30. A...

Oppenheimer Sticks to Its Hold Rating for Marinus (MRNS)

Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics among healthcare movers

Analyst Marc Goodman from Leerink Partners maintained a Buy rating on Marinus (MRNS – Research Report) and decreased the price target to $2.00 from...

Maintaining Buy Rating on Marinus: A Balanced View on Future Prospects Despite RSE Setback

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inspire Medical Systems (INSP – Research Report), El...

Analysts' Top Healthcare Picks: Inspire Medical Systems (INSP), Eli Lilly & Co (LLY)

ATNM

BACK

CGEM

CISS

CRMD

ENLV

FULC

INSP

NEOV

OCUL

OTLK

PALI

PSTX

RXRX

SSNT

VIRX

WISA

YYAI

Press Releases

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm